The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
The BRAFV600E mutation is found in 8–10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months. At present, besides immune checkpoint inhibitors (CPIs) for those tumors with concomitant MSI-H status, recommended treatment options include cytotoxic chemotherapy + anti-VEGF in the first line setting, and a combination of EGFR and a BRAF inhibitor (cetuximab plus encorafenib) in second line. However, even with the latter targeted approach, acquired resistance limits the possibility of more than an incremental benefit and survival is still dismal. In this review, we discuss current treatment options for this subset of patients and perform a systematic review of ongoing clinical trials. Overall, we identified six emerging strategies: targeting MAPK pathway (monotherapy or combinations), targeting MAPK pathway combined with cytotoxic agents, intensive cytotoxic regimen combinations, targeted agents combined with CPIs, oxidative stress induction, and cytotoxic agents combined with antiangiogenic drugs and CPIs. In the future, the integration of new therapeutic strategies targeting key players in the BRAFV600E oncogenic pathways with current treatment approach based on cytotoxic chemotherapy and surgery is likely to redefine the treatment landscape of these CRC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 PRISMA 2009 Flow diagram representing the systematic review performed on ClinicaTrial.gov on 23 December 2020 [65]. For more information, visit www.prisma-statement.org.](https://figures.cochat.ai/paper-figures/f8d8a0504a9147d4be27b5d44f9148f7/the-evolutionary-landscape-of-treatment-for-brafv600e-mutant-metastatic-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple clinical trials reported in recent years have noted significantly improved survival using precision therapeutic approaches that target some of the deadliest mCRC sub-types, including BRAFV600E mutations [13].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Particularly, BRAF mutations account for 8–10% of mCRCs and more than 90% are missense mutations occurring in codon 600, leading to an aminoacidic substitution of a valine for a glutamic acid (V600E) [6].”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 4×
“However, a recent meta-analysis, showing no benefit from FOLFOXIRI plus bevacizumab if compared to standard cytotoxic doublets plus bevacizumab in BRAFV600E mutant mCRC, will lead to reconsider current clinical guidelines recommendations [3,4,53].”
BackgroundMethodInfluentialPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 3×
“In addition, the recent phase III trial KEYNOTE-177 demonstrated the superiority of pembrolizumab in first-line setting over standard regimens in MSI mCRC, independently from BRAF status (Table S1) [35].”
BackgroundOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · cited 2×
“Overall response rate (ORR) and disease control rate (DCR) were 31 and 69% in BRAF wild-type mCRCs and 25 and 75% in BRAFV600E mutant mCRCs [36].”
BackgroundCancer treatment and survivorship statistics, 2014
DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,779
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“In contrast, in a first line setting, BRAFV600E mutation was not identified as a negative predictive biomarker of response to cetuximab or panitumumab added on top to FOLFOX or FOLFIRI, but rather a poor prognostic biomarker [46,47].”
BackgroundSelf-citationOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · cited 3×
“According to these trials, CPIs seem to perform better than standard therapies in BRAFV600E mutant MSI mCRC [25,33,35].”
BackgroundUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 1×
“Subsequently, preclinical studies allowed to shed light on mechanisms of primary resistance to BRAF blockade in this tumor: differently from melanoma, in CRC anti-BRAF monotherapy induces a feedback activation of EGFR that re-activate the oncogenic pathway providing pharmacological escape [27] (Figure 1).”
BackgroundVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 8×
“Furthermore, the use of oxaliplatin or irinotecan does not modify PFS to first-line treatment [39].”
BackgroundResultInfluentialWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“As far as anti-EGFR treatment, initial data generated retrospectively in the advanced lines with cetuximab or panitumumab used as monotherapy, and supported by in vitro data, clearly showed that BRAFV600E mutation is a mechanism of resistance to this treatment [43].”
ResultSelf-citationEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254 · cited 1×
“Similarly to early trials of BRAF targeting in mCRC, this strategy has been derived from melanoma [70,71].”
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 9×
“Progressively, subsequent clinical trials reshaped the therapeutic landscape toward specific targeted or cytotoxic treatment regimens for this subset of patients [25,28].”
BackgroundMethodInfluentialBRAF Mutations in Hairy-Cell Leukemia
Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,024
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021 · cited 6×
“I 60 E mutation represents a poor prognostic factor a i r ll i l ( ) f ti t i it i i t i t ti t e t [7,12]. i l i ll , BRAFV E utant s l , i s tellite instability ( SI) and consensus molec- ular subtype 1 (CMS1) [13].”
BackgroundInfluentialVitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913 · cited 2×
“This killing activity is mediated by the stalling of glyceraldehyde 3-phosphate dehydrogenase, (GAPDH) which causes an energetic crisis in highly glycolytic KRAS and BRAF mutant but not in wild-type CRC cells (Figure 1) [74].”
BackgroundVenderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772 · cited 1×
“First, the percentage of MSI CRC patients enrolled was lower than 10% which appears lower than expected among BRAFV600E mutant mCRC [15,16,62].”
BackgroundCutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Guggenheim, M., Keilholz, U., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds229 · Cited by 714
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 8×
“Furthermore, the use of oxaliplatin or irinotecan does not modify PFS to first-line treatment [39].”
BackgroundResultInfluentialMorris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676 · cited 1×
“One trial (NCT04294160) is evaluating multiple targeted combi ations of BRAF inhibitors, ERK inhibitors, SHIP2 inhibitors or pan-RAF inhibitor (Figure 1) [66,67].”
BackgroundCutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz411 · Cited by 617
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592 · cited 3×
“In this regard, in vitro data suggest considering an upfront convergent targeting with also an ERK inhibitor to prevent resistance [24].”
BackgroundSelf-citationBokemeyer, C., Cutsem, E. V., Rougier, P., Ciardiello, F., Heeger, S., Schlichting, M., Celik, I., & Köhne, C.-H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.057 · Cited by 585 · cited 1×
“In contrast, in a first line setting, BRAFV600E mutation was not identified as a negative predictive biomarker of response to cetuximab or panitumumab added on top to FOLFOX or FOLFIRI, but rather a poor prognostic biomarker [46,47].”
BackgroundYoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · cited 1×
“To assess the real impact of BRAFV600E mutation as predictive biomarker to anti-EGFR treatment, two meta-analyses were published showing conflicting results [48,49].”
ResultMicrosatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Lochhead, P., Kuchiba, A., Imamura, Y., Liao, X., Yamauchi, M., Nishihara, R., Qian, Z. R., Morikawa, T., Shen, J., Meyerhardt, J. A., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt173 · Cited by 442 · cited 1×
“First, the percentage of MSI CRC patients enrolled was lower than 10% which appears lower than expected among BRAFV600E mutant mCRC [15,16,62].”
BackgroundMolecular pathological classification of colorectal cancer
Müller, M. F., Ibrahim, A. E. K., & Arends, M. J. (2016) · Virchows Archiv · doi:10.1007/s00428-016-1956-3 · Cited by 432 · cited 1×
“This is relevant since MSI and microsatellite stable (MSS) mCRCs are well-known to represent two distinct diseases with specific etiology, prognosis and different treatment implications [13,17].”
BackgroundNichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415 · cited 1×
“One trial (NCT04294160) is evaluating multiple targeted combi ations of BRAF inhibitors, ERK inhibitors, SHIP2 inhibitors or pan-RAF inhibitor (Figure 1) [66,67].”
BackgroundSeymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., Lowe, C., Seligmann, J. F., Wadsley, J., Maisey, N., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 388 · cited 2×
“Second, the control arm has been questioned since the use of a regimen including an anti-EGFR in the second line setting is of very limited efficacy [44,45].”
BackgroundJones, J. C., Renfro, L. A., Al-Shamsi, H. O., Schrock, A. B., Rankin, A., Zhang, B. Y., Kasi, P. M., Voss, J. S., Leal, A. D., Sun, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4394 · Cited by 339
Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30862-9 · Cited by 334 · cited 1×
“In contrast, the TRIBE 2 study did not confirmed the advantage of FOLFOXIRI plus bevacizumab versus the doublet regimens plus bevacizumab in the BRAFV600E mutant mCRC patients [52].”
MethodCombined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Ribas, A., Lawrence, D., Atkinson, V., Agarwal, S., Miller, W. H., Carlino, M. S., Fisher, R., Long, G. V., Hodi, F. S., Tsoi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0476-5 · Cited by 323 · cited 1×
“Similarly to early trials of BRAF targeting in mCRC, this strategy has been derived from melanoma [70,71].”
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319 · cited 1×
“However, AVF2107g and AGITG MAX trials showed a numerical improvement in survival outcomes for patients with BRAFV600E mutant mCRC with the addiction of bevacizumab to cytotoxic agents [40,41].”
BackgroundRowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319 · cited 1×
“To assess the real impact of BRAFV600E mutation as predictive biomarker to anti-EGFR treatment, two meta-analyses were published showing conflicting results [48,49].”
ResultWu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
Rosenbaum, M. W., Bledsoe, J. R., Morales-Oyarvide, V., Huynh, T. G., & Mino-Kenudson, M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.95 · Cited by 288 · cited 1×
“death ligand-1 (PD-L1) and the presence of BRAFV600E mutation has been shown, with also higher levels of CD8+ tumor-infiltrating lymphocytes [72].”
BackgroundHigh-dose vitamin C enhances cancer immunotherapy
Magrì, A., Germano, G., Lorenzato, A., Lamba, S., Chilà, R., Montone, M., Amodio, V., Ceruti, T., Sassi, F., Arena, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8707 · Cited by 285 · cited 1×
“Recently, an enhanced activity of CPIs induced by concomitant administration of vitamin C has been reported [75].”
BackgroundYaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276 · cited 2×
“One of them is a phase II trial (NCT03727763) combines FOLFIRI with cetuximab and vemurafenib based on previous encouraging data combining irinotecan with anti-BRAF molecules [58,59].”
BackgroundCremolini, C., Antoniotti, C., Stein, A., Bendell, J., Gruenberger, T., Rossini, D., Masi, G., Ongaro, E., Hurwitz, H., Falcone, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01225 · Cited by 235 · cited 3×
“This has been recently confirmed by a meta-analysis from the same group, demonstrating no benefit from FOLFOXIRI plus bevacizumab if compared to standard doublet cytotoxic combinations [53].”
BackgroundMethodResultvan Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232 · cited 2×
“2 months for the doublet and triplet, respectively [64].”
BackgroundBRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Barras, D., Missiaglia, E., Wirapati, P., Sieber, O. M., Jorissen, R. N., Love, C., Molloy, P. L., Jones, I. T., McLaughlin, S., Gibbs, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0140 · Cited by 230 · cited 4×
“BM1 is less common (1/3 of cases) and is characterized by strong activation of AKT/mTOR, KRAS, 4EBP1 and epithelial-mesenchymal transition features [79].”
BackgroundInfluentialRowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 229
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219 · cited 2×
“One of them is a phase II trial (NCT03727763) combines FOLFIRI with cetuximab and vemurafenib based on previous encouraging data combining irinotecan with anti-BRAF molecules [58,59].”
BackgroundPrice, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A., Townsend, A. R., Wrin, J. W., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 209 · cited 1×
“However, AVF2107g and AGITG MAX trials showed a numerical improvement in survival outcomes for patients with BRAFV600E mutant mCRC with the addiction of bevacizumab to cytotoxic agents [40,41].”
BackgroundFOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., Michelucci, A., Pfanner, E., Brunetti, I., Lupi, C., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.024 · Cited by 186 · cited 2×
“However, around 20% of patients with BRAFV600E mCRC patients survives beyond 24 months from the initial diagnosis [12,28,51,77,78].”
BackgroundPeeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181 · cited 2×
“Second, the control arm has been questioned since the use of a regimen including an anti-EGFR in the second line setting is of very limited efficacy [44,45].”
BackgroundCremolini, C., Bartolomeo, M. D., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv290 · Cited by 173 · cited 1×
“Differently from BRAFV600E mutant mCRC, BRAFnon-V600E mutant mCRC are usually left-sided, non-mucinous, MSS, without peritoneal involvement leading to a better OS, and not requiring the same treatment approach [7,8,11].”
BackgroundSelf-citationSchirripa, M., Bergamo, F., Cremolini, C., Casagrande, M., Lonardi, S., Aprile, G., Yang, D., Marmorino, F., Pasquini, G., Sensi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.142 · Cited by 172
Seligmann, J. F., Fisher, D., Smith, C. G., Richman, S. D., Elliott, F., Brown, S., Adams, R., Maughan, T., Quirke, P., Cheadle, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw645 · Cited by 165 · cited 8×
“Considering the high number of BRAFV600E mutant mCRC patients who will never receive a second-line treatment, the rational of this strategy is to maximize treatment outcome within the first-line setting [11,12].”
BackgroundInfluentialStintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 152 · cited 2×
“Interestingly, the FIRE-3 trial is a first-line setting study which compared FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab [50].”
BackgroundTosi, F., Magni, E., Amatu, A., Mauri, G., Bencardino, K. B., Truini, M., Veronese, S. M., Carlis, L. G. D., Ferrari, G. C., Nichelatti, M., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.004 · Cited by 137 · cited 2×
“Although rarely BRAFV600E mutant mCRC patients present with liver or lung limited disease, international clinical guidelines recommend evaluating feasibility of surgical resection with curative intent in oligometastatic disease given its long-term survival implication [29,30].”
BackgroundSelf-citationMorris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132 · cited 2×
“Standard doublet chemotherapy leads to poor outcome in terms of progression-free survival (PFS) in advanced mCRC harboring BRAFV600E mutation in first-, second- and third-line treatment [39].”
BackgroundThe heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
Fanelli, G. N., Pozzo, C. A. D., Depetris, I., Schirripa, M., Brignola, S., Biason, P., Balistreri, M., Santo, L. D., Lonardi, S., Munari, G., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1117-2 · Cited by 129 · cited 5×
“Considering the high number of BRAFV600E mutant mCRC patients who will never receive a second-line treatment, the rational of this strategy is to maximize treatment outcome within the first-line setting [11,12].”
BackgroundInfluentialOddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Self-citationCapper, D., Voigt, A., Bozukova, G., Ahadova, A., Kickingereder, P., von Deimling, A., von Knebel Doeberitz, M., & Kloor, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28183 · Cited by 109
Schirripa, M., Biason, P., Lonardi, S., Pella, N., Pino, M. S., Urbano, F., Antoniotti, C., Cremolini, C., Corallo, S., Pietrantonio, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0311 · Cited by 102 · cited 3×
“I 60 E mutation represents a poor prognostic factor a i r ll i l ( ) f ti t i it i i t i t ti t e t [7,12].”
BackgroundMolecular targeted therapy of BRAF-mutant colorectal cancer
Ducreux, M., Chamseddine, A., Laurent-Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samallin, E., Boige, V., Malka, D., & Gelli, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919856494 · Cited by 100 · cited 1×
“However, around 20% of patients with BRAFV600E mCRC patients survives beyond 24 months from the initial diagnosis [12,28,51,77,78].”
BackgroundRenaud, S., Romain, B., Falcoz, P., Olland, A., Santelmo, N., Brigand, C., Rohr, S., Guénot, D., & Massard, G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.499 · Cited by 90
Exploring the best treatment options for BRAF-mutant metastatic colon cancer
Taieb, J., Lapeyre-Prost, A., Laurent Puig, P., & Zaanan, A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0526-2 · Cited by 74 · cited 7×
“V600E mutation causes an inappropriate cti ti f t is at ay lea i g to co trolle cell roliferatio , igratio , a gioge esis, a esca e fro apoptosis [18] (Figure 1).”
BackgroundInfluentialLoupakis, F., Intini, R., Cremolini, C., Orlandi, A., Sartore-Bianchi, A., Pietrantonio, F., Pella, N., Spallanzani, A., Dell’Aquila, E., Scartozzi, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.008 · Cited by 69
Self-citationKayhanian, H., Goode, E., Sclafani, F., Ang, J. E., Gerlinger, M., de Castro, D. G., Shepherd, S. T. C., Peckitt, C., Rao, S., Watkins, D. J., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.006 · Cited by 67
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 65 · cited 1×
“Differently from recent publications on this topic [11,18,76], in this review we focused on ongoing clinical trials with the aim to define future developments of treatment for this subset of patients [11,18,76] (Figure 3).”
BackgroundVelour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.
Wirapati, P., Pomella, V., Vandenbosch, B., Kerr, P., Maiello, E., Jeffery, G. M., Curca, R.-O. D., Karthaus, M., Bridgewater, J. A., Mihailov, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3538 · Cited by 56
Shattuck-Brandt, R. L., Chen, S., Murray, E., Johnson, C. A., Crandall, H., O’Neal, J. F., Al-Rohil, R. N., Nebhan, C. A., Bharti, V., Dahlman, K. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1895 · Cited by 50 · cited 3×
“A further study (NCT03714958) is testing the option of targeting the P53 inhibitor MDM2 and MEK [68,69].”
BackgroundJohnson, B., Jin, Z., Truty, M. J., Smoot, R. L., Nagorney, D. M., Kendrick, M. L., Kipp, B. R., & Grothey, A. F. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0230 · Cited by 47 · cited 2×
“Although rarely BRAFV600E mutant mCRC patients present with liver or lung limited disease, international clinical guidelines recommend evaluating feasibility of surgical resection with curative intent in oligometastatic disease given its long-term survival implication [29,30].”
BackgroundCorcoran, R. B., Giannakis, M., Allen, J. N., Chen, J. Y., Pelka, K., Chao, S. X., Meyerhardt, J. A., Enzinger, A. C., Enzinger, P. C., McCleary, N. J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.041 · Cited by 44 · cited 7×
“Overall response rate (ORR) and disease control rate (DCR) were 31 and 69% in BRAF wild-type mCRCs and 25 and 75% in BRAFV600E mutant mCRCs [36].”
BackgroundInfluentialGrothey, A. F., Tabernero, J. M., Taı̈eb, J., Yaeger, R. D., Yoshino, T., Maiello, E., Élez, E., Casado, A. R., Ross, P. J., André, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.080 · Cited by 37 · cited 3×
“Based on the BEACON results, the active but not recruiting phase II ANCHOR-CRC trial is going to explore the role of the triplet combination in first-line setting [63].”
MethodInfluentialHata, A. N., Rowley, S., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Ji, F., Jung, J., Light, M., Lee, J. S., Debussche, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.258 · Cited by 34 · cited 3×
“A further study (NCT03714958) is testing the option of targeting the P53 inhibitor MDM2 and MEK [68,69].”
BackgroundEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Sharma, V., & Vanidassane, I. (2020) · New England Journal of Medicine · doi:10.1056/nejmc1915676 · Cited by 25
Geißler, M., Klingler, T., Knorrenschild, J. R., Tannapfel, A., Greeve, J. C., Seufferlein, T. T. W., Kanzler, S., Held, S., Heinemann, V., Reinacher-Schick, A. C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy281.001 · Cited by 8 · cited 2×
“TRIBE and VOLFI trials do support a potential benefit of this approach [28,54].”
BackgroundResult
Cited by
Crisafulli, G., Bianchi, A. S., Lazzari, L., Pietrantonio, F., Amatu, A., Macagno, M., Barault, L., Cassingena, A., Bartolini, A., Luraghi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1434 · Cited by 147
Self-citationHarnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Self-citationAl-Joufi, F., Setia, A., Salem-Bekhit, M. M., Sahu, R. K., Alqahtani, F. Y., Widyowati, R., & Aleanizy, F. (2022) · Nanomaterials · doi:10.3390/nano12010169 · Cited by 94
“People with BRAF mutation and microsatellite instability-high (MSI-H) tumours had a better overall prognosis than people with BRAF mutation and microsatellite stable (MSS) illness, and it turns out, using MSI to screen for Lynch syndrome and identify patients who could benefit from immunotherapy is becoming increasing…”
BackgroundRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
Metadata
- Authors
- Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., Siena, S., & Sartore-Bianchi, A.
- Affiliations
- University of Milan (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milano, Italy
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-04
- Volume
- 13
- Issue
- 1
- Pages
- 137
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7795863
- OpenAlex
- W3119715349
- Cited by
- 73
- References
- 79
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 25 · 2023: 14 · 2022: 20 · 2021: 10
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fondazione Regionale Ricerca Biomedica Regione Lombardia (Project CP 12/2018 IANG CRC)
- H2020 grant agreement MoTriColor (no. 635342-2)
- AIRC IG (no. 20685)
- Terapia Molecolare Tumori by Fondazione Oncologia Niguarda Onlus (NA)
- FONDAZIONE AIRC under 5 per Mille 2018 (ID. 21091 program)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, metastatic colorectal cancer, MAPK signaling, cetuximab, encorafenib, immune checkpoint inhibitors, acquired drug resistance, anti-VEGF therapy, cytotoxic chemotherapy, oxidative stress, antiangiogenic drugs, combination therapy, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.